Conference abstractPublished 18 Jul 2016
Dendrimers: Anti-angiogenic nanomaterials for treatment of cancer
National Institute of Pharmaceutical Education and Research, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Formation of new blood vessels from pre-existing blood vessels i.e. angiogenesis play crucial role in the metastasis and growth of tumor, and hence inhibition of neo-vascularization could be a lucrative approach in the successful treatment of cancer. Numerous preclinical investigational studies showed that the combined treatment of cancer with angiogenesis and chemotherapy/radiotherapy could result in improved outcomes as compared to chemotherapy and/or radiotherapy. In this regard we could postulate that the designing of a nano-material with anti-angiogenic activity and potential to deliver anticancer drug selectively to cancer cells may emerge as a promising therapeutic approach for treatment of cancer. Dendrimers represent a well defined three-dimensional macromolecular structure synthesized in a step-wise controlled manner with nearly mono-disperse polymeric architecture. Some dendrimer molecules including poly-L-lysine (PLL) dendrimers, poly-arginine dendrimers with glycine core, poly(propylene imine) (PPI) dendrimers with surface arginine groups have shown intrinsic anti-angiogenic activity in previous reports including from our laboratory. Particularly PLL dendrimers have been investigated thoroughly for anti-angiogenic activity and showed reduced vascularization, significant reduction in apoptosis/necrosis of tumor tissue and moderate regression effect on tumor growth equivalent to commercially available antiangiogenic agent, Avastin (anti-VEGF antibody bevacizumab) without significant toxic effect on non-cancerous tissues. In this presentation I will enlighten the progress made in design of anti-angiogenic dendrimers, dendrimers as nano-carrier for delivery of anticancer drugs and future possibilities to improve treatment strategies for cancer via two pronged attack on cancer with anti-angiogenic dendrimers and chemotherapeutic agents including reports from our laboratory and other laboratories as well.
Subjects
NanotechnologyOncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectNanotechnology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Keerti Jain”